Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 2115-2127

  Santos, Diego M ^a   Carneiro, Marcia W ^a   de Moura, Tatiana R ^a   Fukutani, Kiyoshi ^a   Clarencio, Jorge ^a   Soto, Manuel ^b   Espuelas, Socorro ^c,d   Brodskyn, Claudia ^a,e   Barral, Aldina ^a,e   Barral Netto, Manoel ^a,e   de Oliveira, Camila I ^a,e  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c Historia y Legislación Farmacéutica   (Spain)

^d UNIVERSITY OF NAVARRA   (Spain)

^e Institute de Investigação em Imunologia iii   (Brazil)

Author keywords

Kinetoplastid membrane protein 11; Leishmania; Nanoparticle; Vaccine

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; KINETOPLASTID MEMBRANE PROTEIN 11; LEISHMANIA VACCINE; NANOPARTICLE; PLASMID DNA; POLYGLACTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; DNA VACCINE; LACTIC ACID; PARASITE ANTIGEN; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; RECOMBINANT PROTEIN;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FEMALE; HUMORAL IMMUNITY; INFECTION PREVENTION; LEISHMANIASIS; MOUSE; NONHUMAN; PARASITE LOAD; SKIN LEISHMANIASIS; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CHEMISTRY; EVALUATION; GENETICS; IMMUNOLOGY; LEISHMANIA BRAZILIENSIS; METABOLISM; NANOMEDICINE; PARASITOLOGY; PLASMID;

KINETOPLASTIDA; LEISHMANIA BRAZILIENSIS; LEISHMANIA INFANTUM; MUS; PHLEBOTOMINAE; PROTOZOA;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CYTOKINES; DRUG DELIVERY SYSTEMS; FEMALE; IMMUNITY, CELLULAR; LACTIC ACID; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS VACCINES; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; NANOMEDICINE; NANOPARTICLES; PLASMIDS; POLYGLYCOLIC ACID; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; VACCINES, DNA;

EID: 84866749418     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S30093     Document Type: Article

References (46)

1. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis. 2004;27(5):305-318.
2. Marsden PD. Mucosal leishmaniasis ("espundia" Escomel, 1911). Trans R Soc Trop Med Hyg. 1986;80(6):859-876.
3. Bittencourt A, Barral-Netto M. Leishmaniasis. Vol 8. 2nd ed. Doerr W, Seifert G, editors. Tropical Pathology. Berlin: Springer; 1995.
4. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol. 2006;22(12):552-557.
5. Scott P, Natovitz P, Coffman RL, Pearce E, Sher A. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med. 1988;168(5):1675-1684.
6. Liew FY, Millott S, Parkinson C, Palmer RM, Moncada S. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol. 1990;144(12):4794-4797.
7. de Oliveira CI, Nascimento IP, Barral A, Soto M, Barral-Netto M. Challenges and perspectives in vaccination against leishmaniasis. Parasitol Int. 2009;58(4):319-324.
8. Okwor I, Uzonna J. Vaccines and vaccination strategies against human cutaneous leishmaniasis. Hum Vaccin. 2009;5(5):291-301.
9. Ramshaw IA, Ramsay AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today. 2000;21(4):163-165.
10. Ramiro MJ, Zarate JJ, Hanke T, et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine. 2003;21(19-20):2474-2484.
11. Dondji B, Perez-Jimenez E, Goldsmith-Pestana K, Esteban M, McMahon-Pratt D. Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect Immun. 2005;73(8):5286-5289.
12. Rafati S, Zahedifard F, Azari MK, Taslimi Y, Taheri T. Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice. Exp Parasitol. 2008;118(3):393-401.
13. Gonzalo RM, del Real G, Rodriguez JR, et al. A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine. 2002;20(7-8):1226-1231.
14. Tapia E, Perez-Jimenez E, Lopez-Fuertes L, Gonzalo R, Gherardi MM, Esteban M. The combination of DNA vectors expressing IL-12 EEIL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK. Microbes Infect. 2003;5(2):73-84.
15. Abdian N, Gholami E, Zahedifard F, Safaee N, Rafati S. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis. Exp Parasitol. 2011;127(3):627-636.
16. O'Hagan DT, Rahman D, McGee JP, et al. Biodegradable microparticles as controlled release antigen delivery systems. Immunology. 1991;73(2): 239-242.
17. Carcaboso AM, Hernandez RM, Igartua M, Rosas JE, Patarroyo ME, Pedraz JL. Potent, long lasting systemic antibody levels and mixed Th1/ Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine. 2004;22(11-12):1423-1432.
18. Hamdy S, Molavi O, Ma Z, et al. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8ppT cell-mediated anti-tumor immunity. Vaccine. 2008; 26(39):5046-5057.
19. Chong CSW, Cao M, Wong WW, et al. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J Control Release. 2005;102(1):85-99.
20. Doroud D, Zahedifard F, Vatanara A, et al. Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection. J Control Release. 2011;153(2):154-162.
21. Tafaghodi M, Khamesipour A, Jaafari MR. Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN. Parasitol Res. 2011;108(5): 1265-1273.
22. Jardim A, Funk V, Caprioli RM, Olafson RW. Isolation and structural characterization of the Leishmania donovani kinetoplastid membrane protein-11, a major immunoreactive membrane glycoprotein. Biochem J. 1995;305(Pt 1):307-313.
23. Jensen AT, Gasim S, Ismail A, et al. Humoral and cellular immune responses to synthetic peptides of the Leishmania donovani kinetoplastid membrane protein-11. Scand J Immunol. 1998;48(1):103-109.
24. Thomas MC, Garcia-Perez JL, Alonso C, Lopez MC. Molecular characterization of KMP11 from Trypanosoma cruzi: a cytoskeletonassociated protein regulated at the translational level. DNA Cell Biol. 2000;19(1):47-57.
25. Basu R, Bhaumik S, Basu JM, Naskar K, De T, Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and-resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1-and Th2-like responses in visceral leishmaniasis. J Immunol. 2005;174(11): 7160-7171.
26. Bhaumik S, Basu R, Sen S, Naskar K, Roy S. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. Vaccine. 2009;27(9):1306-1316.
27. Costa CH, Peters NC, Maruyama SR, de Brito EC Jr, Santos IK. Vaccines for the leishmaniases: proposals for a research agenda. PLoS Negl Trop Dis. 2011;5(3):e943.
28. Fuertes MA, Perez JM, Soto M, Lopez MC, Alonso C. Calciuminduced conformational changes in Leishmania infantum kinetoplastid membrane protein-11. J Biol Inorg Chem. 2001;6(1):107-117.
29. Fuertes MA, Berberich C, Lozano RM, Gimenez-Gallego G, Alonso C. Folding stability of the kinetoplastid membrane protein-11 (KMP-11) from Leishmania infantum. Eur J Biochem.1999;260(2): 559-567.
30. del Barrio GG, Novo FJ, Irache JM. Loading of plasmid DNA into PLGA microparticles using TROMS (total recirculation one-machine system): evaluation of its integrity and controlled release properties. J Control Release. 2003;86(1):123-130.
31. Iborra S, Carrion J, Anderson C, Alonso C, Sacks D, Soto M. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice. Infect Immun. 2005;73(9):5842-5852.
32. de Moura TR, Novais FO, Oliveira F, et al. Toward a novel experimental model of infection to study American cutaneous leishmaniasis caused by Leishmania braziliensis. Infect Immun. 2005;73(9):5827-5834.
33. de Moura TR, Oliveira F, Rodrigues GC, et al. Immunity to Lutzomyia intermedia saliva modulates the inflammatory environment induced by Leishmania braziliensis. PLoS Negl Trop Dis. 2010;4(6):e712.
34. de Moura TR, Oliveira F, Novais FO, et al. Enhanced Leishmania braziliensis infection following pre-exposure to sandfly saliva. PLoS Negl Trop Dis. 2007;1(2):e84.
35. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta c(t) method. Methods. 2001;25(4):402-408.
36. Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials. 2010;31(26):6867-6875.
37. Krug A, Rothenfusser S, Hornung V, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001;31(7): 2154-2163.
38. de Carvalho LP, Soto M, Jeronimo S, et al. Characterization of the immune response to Leishmania infantum recombinant antigens. Microbes Infect. 2003;5(1):7-12.
39. Carvalho LP, Passos S, Dutra WO, et al. Effect of LACK and KMP11 on IFN-gamma production by peripheral blood mononuclear cells from cutaneous and mucosal leishmaniasis patients. Scand J Immunol. 2005;61(4):337-342.
40. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD44 CD25CCregulatory T cells control Leishmania major persistence and immunity. Nature. 2002;420(6915):502-507.
41. Singh M, Briones M, Ott G, O'Hagan D. Cationic microparticles: a potent delivery system for DNA vaccines. Proc Natl Acad Sci U S A. 2000;97(2):811-816.
42. Doroud D, Zahedifard F, Vatanara A, Najafabadi AR, Rafati S. Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice. Parasite Immunol. 2011;33(6):335-348.
43. Rice-Ficht AC, Arenas-Gamboa AM, Kahl-McDonagh MM, Ficht TA. Polymeric particles in vaccine delivery. Curr Opin Microbiol. 2010; 13(1):106-112.
44. Storni T, Kundig TM, Senti G, Johansen P. Immunity in response to particulate antigen-delivery systems. Adv Drug Deliv Rev. 2005;57(3): 333-355.
45. Salay G, Dorta ML, Santos NM, et al. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World. Clin Vaccine Immunol. 2007;14(9):1173-1181.
46. Tonui WK, Titus RG. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. major soluble promastigote exogenous antigens in BALB/c mice. Am J Trop Med Hyg. 2007;76(3):579-584.